amid uncertainti downgrad hold pt
rate downgrad hold buy price target reduc
although key reason share
govern push shift product prescript non-
prescript over-the-count remain intact much uncertainti
gener place us sidelin pressur consum america
caus anim health non-cor busi eventu eas
competit reduc price driven greater effici fda
buyer consolid immun secular
challeng gener believ suppli chain issu
poor execut ad rather offset challeng
amid uncertainti would prefer see stabil gener
evid split gener busi consum
busi execut effect get construct
share result downgrad hold buy
lower price target
 gener
prgo valuat danger includ govern discount investor
appear concern candid commun
regard ceo chang one month ago assur us
guidanc time reflect belief good gandrogel launch
howev sinc follow launch becam clear abbvi
launch author gener would problemat nevertheless
releas shift delay investor day two guidanc reduct
thu strike us trade steep discount peer vs
histor premium investor may price reset estim
also worryingli govern discount similar gener peer
refer exhibit report
consum busi well posit long-term growth
growth america busi estim repres
approxim pro forma sale pro forma oper
profit eventu acceler result favor govern
polici busi streamlin suppli chain
improv inventori manag drive margin-
enhanc save thu clariti emerg gener think
share could becom compel
price target base weighted-averag valu result
sotp analysi dcf
chang made note
page analyst certif
perform rel
co plc engag product
over-the-count consum good
profit loss summari
growth margin
domin share privat label store brand
market solid presenc european brand over-the-counter
chca busi benefit renew regulatori
legisl focu over-the-counter
account oversight improv
chci busi stabil growth continu
rx busi challeng secular
declin gener industri intern execut issu
keep us sidelin
valu base weighted-averag valu
result sum-of-the-part analysi sotp dcf
chang net debt
average cost debt
risk invest thesi
less favor impact govern regulatori chang
 consum busi repres key downsid risk
improv gener repres key upsid risk risk
thesi includ increas competit gener pressur
rx busi expect turnaround
eu stall regulatori risk price risk litig risk
exhibit reduc guidanc
million unless otherwis note
sale
sale
segment sale
segment sale
segment sale
interest exp
note provid certain line item back other
near-term estim consensu
exhibit reduc estim primarili owe assumpt continu margin
weak gener abl prove gener margin sustain
rang long term may reassess assumpt
despit best effort execut success turnaround prior three
year valuat remain depress think may reflect
fundament risk busi particular trade steep
discount peer though may reflect risk gener busi
compani expos may also reflect govern discount built
valuat instanc next-twelve-month ntm ev-to-consensu
ebitda think appropri price-to-earnings given high leverag
histor trade current five-year averag ten-
year averag among select peer multipl contract
prior ten year gener player multipl contract though
surpris given secular challeng note poor corpor
govern track record earn steep discount peer current
prior ten year averag move histor ten-year averag premium
gener peer respect discount versu
peer versu global gener peer base current multipl
view valuat danger includ perman steep discount
similar unless new board manag team prove
commun clearli effect investor execut plan caus
discount vari fundament deterior almost immedi
convinc sharehold rebuff rich offer offer today worth
approxim myl current share price vs close price
els equal fundament seem stabil deterior
danger sharehold investor begin view
govern similar len view mylan board manag
may best interest sharehold mind therefor requir
discount valuat includ risk clear believ perrigo
manag sharehold best interest mind howev recogn
percept risk could make way valuat think
first step take counter percept host thorough credibl
investor meet outlin clear concis strategi consum busi
gener busi agenda particularli
intend separ busi simultan stabil fundament
outsid look challeng yet reschedul
previous plan investor meet switch call
switch back in-person meet postpon notic
exhibit trade discount peer current versu histor premium ntm ev/ebitda
exhibit novemb averag monthli
ev/ebitda multipl less ten-year averag
exhibit trade discount peer
compar averag premium
express ntm ev/ebitda multipl
express ntm ev/ebitda rel multipl
rel select move consum good
exhibit trade discount global gener
peer compar averag premium
exhibit trade pariti compar
averag premium
express ntm ev/ebitda rel multipl
express ntm ev/ebitda rel multipl
rel global gener
rel
exhibit price-to-earnings trade discount
 versu ten-year averag premium
express ntm price-to-earnings rel multipl
rel
exhibit price-to-earnings trade discount
peer compar averag premium
express ntm price-to-earnings rel multipl
rel select move consum good
valuat lower pt
price target base sum-of-th part sotp analysi dcf valu
creation sale scenario may challeng primarili think perrigo
would will sell price less averag multipl global player also
unsur balanc sheet larger player would abl handl pay
gener busi likewis tax implic may make
less will pursu rout littl visibl potenti capit gain
tax associ sale suggest prior meet
view tax burden oner prevent sale outright nonetheless
spin scenario particular revers morri trust rmt share spinco
gener may convert share suitor may make sens
valuat tax perspect present spin scenario valuat part though
pursu rmt spinco share would convert share
whichev suitor purchas busi
million unless otherwis note
equival
declin modest ebitda
declin declin
depreci total
assum valuat
current global gener
flat though
ebitda margin fall
debt reduct necessari
multipl
excess cash may use
depend valuat
tax paid sale
gener may dilut
base busi
driven clariti growth
penetr over-the-counter brand
over-the-counter expans
 govern
million unless otherwis note
equival
equival
flat though
ebitda margin fall
debt necessari maintain
leverag multipl
base busi
driven clariti growth
penetr over-the-counter brand
over-the-counter expans
 govern
declin declin
depreci total
assum focus
execut anda
submiss new
fundament
new price target base weighted-averag valu result
sale spin scenario sotp analysi dcf arriv valu
base discount rate termin ev/ebitda multipl think
long-term dcf better captur long-term over-the-counter opportun
though potenti take three five year fulli develop could price somewhat
follow announc govern sponsor regard
exhibit weight price target
main risk thesi relat view regul legisl
stabil gener regulatori legisl solut implement
 reduc prescript drug cost inflat includ increas access non-
prescript drug posit impact think
assumpt model call acceler fundament may
optimist similarli better execut gener could stabil busi faster
assum risk thesi includ increas competit gener pressur
perrigo rx busi expect turnaround eu stall regulatori
risk price risk litig risk busi develop risk among other
profit loss account
million unless otherwis note
sale
sale
sale
sale
sale
sale
sale
total expens
total expens
total expens
total expens
sale
sale
 year
reconcili gaap
reconcili gaap
reconcili gaap
reconcili gaap
million unless otherwis note
cash equival
prepaid expens
properti plant equip net
goodwil
payrol relat tax
accumul incom loss
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
million unless otherwis note
depreci amort
loss acquisition-rel fx
chang financi asset
tysabri chang fair valu
incom tax benefit stock option
excess tax benefit stock transact
loss sale invest
loss sale busi
loss extinguish debt
loss equiti method invest
amort debt discount premium
chang work capit
chang work capit
chang work capit
chang work capit
payrol relat tax
total chang work capit
oper activ
oper activ
oper activ
oper activ
acquisit busi
proce royalti right
purchas invest secur
settlement acquisition-rel fx
acquisit intang asset
addit properti equip
proce sale secur
proce sale pp
proce sale tysabri
proce sale busi
invest activ
invest activ
invest activ
invest activ
purchas non-controlling interest
repay long-term debt
borrow repay revolv
proce debt issuanc
premium earli retir debt
share withheld tax liabil
excess tax benefit stock transact
issuanc common stock
equiti issuanc
repurchas common stock
settlement conting consider
financ activ
financ activ
financ activ
financ activ
effect exchang rate cash
net chang cash
begin cash equival
end cash equival
end cash equival
end cash equival
end cash equival
capital-expenditure sale
